Evidence map›Paper›PMID 28126460›Full record

ArticleThe lancet. Diabetes & endocrinology2017

Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys.

Peter Ueda, Mark Woodward, Yuan Lu, Kaveh Hajifathalian, Rihab Al-Wotayan, Carlos A Aguilar-Salinas, Alireza Ahmadvand, Fereidoun Azizi, James Bentham, Renata Cifkova and 26 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in The lancet. Diabetes & endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03512691 (The Nueva Ecija Cardiovascular Risk Experiment), which is not on this map. Cited by 82 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 4 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03512691 naunknown statusnot on this mapstarted 2018, after this paper: background citation

The Nueva Ecija Cardiovascular Risk Experiment: An Evaluation of the Impact of Risk Information and Screening on Primary Prevention of Cardiovascular Disease

TypeinterventionalSponsorUPecon Foundation, Inc.Ran2018 to 2021Enrolled5,019ConditionsCardiovascular Diseases, Cardiovascular Risk FactorArmsInformation on CVD Risk, Lottery Incentive
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 4 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Risk scores for type 2 diabetes mellitus in Latin America: a systematic review of population-based studies.Diabetic medicine : a journal of the British Diabetic Association · 2019
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Cardiovascular Risk Prediction in Older Adults.Current atherosclerosis reports · 2025
    Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 16 countries.

Peter UedaDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA, USA.
Mark WoodwardThe George Institute for Global Health, University of Oxford, Oxford, UK; The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia; Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
Yuan LuYale/Yale-New Haven Hospital, Center for Outcomes Research and Evaluation, New Haven, CT, USA.
Kaveh HajifathalianDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Rihab Al-WotayanCentral Department of Primary Health Care, Ministry of Health, Kuwait City, Kuwait.
Carlos A Aguilar-SalinasDepartment of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, "Salvador Zubirán", Mexico City, Mexico.
Alireza AhmadvandMRC-PHE Centre for Environment and Health, Imperial College London, London, UK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Fereidoun AziziEndocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
James BenthamDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Renata CifkovaCenter for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic.
Mariachiara Di CesareMRC-PHE Centre for Environment and Health, Imperial College London, London, UK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; Department of Natural Sciences, School of Science and Technology, Middlsex University, London, UK.
Louise EriksenNational Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.
Farshad FarzadfarNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Trevor S FergusonEpidemiology Research Unit, Caribbean Institute for Health Research, The University of the West Indies, Kingston, Jamaica.
Nayu IkedaCenter for International Collaboration and Partnership, National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo, Japan.
Davood KhaliliPrevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Young-Ho KhangInstitute of Health Policy and Management, Seoul National University College of Medicine, Seoul, South Korea.
Vera LanskaStatistical Unit, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Luz León-MuñozDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/Idipaz, and CIBER of Epidemiology and Public Health, Madrid, Spain.
Dianna J MaglianoBaker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
Paula MargozziniDepartment of Public Health, Faculty of Medicine, Pontifical Catholic University of Chile, Santiago, Chile.
Kelias P MsyambozaWHO, Malawi Country Office, Lilongwe, Malawi.
Gerald MutungiNon-communicable Diseases Prevention and Control Program at the Ministry of Health, Kampala, Uganda.
Kyungwon OhDivision of Health and Nutrition Survey, Korea Centers for Disease Control and Prevention, Cheongwon-gun, South Korea.
Sophal OumUniversity of Health Sciences, Phnom Penh, Cambodia.
Fernando Rodríguez-ArtalejoDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/Idipaz, and CIBER of Epidemiology and Public Health, Madrid, Spain.
Rosalba Rojas-MartinezCentro de Investigación en Salud Poblacional, Instituto Nacional de Salud Publica, Cuernavaca, Mexico.
Gonzalo ValdiviaDivisión Salud Pública y Medicina Familiar, Pontificia Universidad Católica de Chile, Santiago, Chile.
Rainford WilksEpidemiology Research Unit, Caribbean Institute for Health Research, The University of the West Indies, Kingston, Jamaica.
Jonathan E ShawBaker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
Gretchen A StevensDepartment of Information, Evidence and Research, WHO, Geneva, Switzerland.
Janne S TolstrupNational Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.
Bin ZhouMRC-PHE Centre for Environment and Health, Imperial College London, London, UK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Joshua A SalomonDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA, USA.
Majid EzzatiMRC-PHE Centre for Environment and Health, Imperial College London, London, UK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; WHO Collaborating Centre on NCD Surveillance and Epidemiology, Imperial College London, London, UK; Wellcome Trust Centre for Global Health Research, London, UK.
Goodarz DanaeiDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. Electronic address: gdanaei@hsph.harvard.edu.
Imperial College London · GBBaker Heart and Diabetes Institute · AUHarvard Global Health Institute · USPontificia Universidad Católica de Chile · CLShahid Beheshti University of Medical Sciences · IRUniversity of Southern Denmark · DKUniversity of the West Indies · JMCentro de Investigación Biomédica en Red · ESCharles University · CZCleveland Clinic · USHarvard University · USInstitute of Clinical and Experimental Medicine · CZInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXInstituto Nacional de Salud Pública · MXKorea Disease Control and Prevention Agency · KRMinistry of Health · UGMinistry of Health · KWNational Institute of Infectious Diseases · JPSeoul National University Hospital · KRTehran University of Medical Sciences · IR

Funding

UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SUSAN M. SMITH · 1999 to 2026
$31.6M
MONITORING SOCIAL CHANGE: HEALTH, REPRODUCTION, AGINGR01HD030880 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ADAIR, LINDA S, POPKIN, BARRY M · 1994 to 2024
$27.0M
Carolina Population CenterR24HD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MORGAN, SAMUEL PHILIP · 2005 to 2014
$10.0M
Reducing disparities in diabetes through expanded insurance coverage.R01DK090435 · NIDDK · HARVARD SCHOOL OF PUBLIC HEALTH · PI DANAEI, GOODARZ · 2011 to 2014
$1.8M
CHILD HEALTH EFFECTS OF RAPID SOCIO-DEMOGRAPHIC CHANGER01HD038700 · NICHD · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI POPKIN, BARRY M · 2000 to 2004
$1.5M
NICHD NIH HHS R01 HD030880NICHD NIH HHS R01 HD038700NICHD NIH HHS R24 HD050924NIDDK NIH HHS P30 DK056350NIDDK NIH HHS R01 DK090435Wellcome Trust 100693
6 · The paper itself

Abstract

backgroundWorldwide implementation of risk-based cardiovascular disease (CVD) prevention requires risk prediction tools that are contemporarily recalibrated for the target country and can be used where laboratory measurements are unavailable. We present two cardiovascular risk scores, with and without laboratory-based measurements, and the corresponding risk charts for 182 countries to predict 10-year risk of fatal and non-fatal CVD in adults aged 40-74 years.

methodsBased on our previous laboratory-based prediction model (Globorisk), we used data from eight prospective studies to estimate coefficients of the risk equations using proportional hazard regressions. The laboratory-based risk score included age, sex, smoking, blood pressure, diabetes, and total cholesterol; in the non-laboratory (office-based) risk score, we replaced diabetes and total cholesterol with BMI. We recalibrated risk scores for each sex and age group in each country using country-specific mean risk factor levels and CVD rates. We used recalibrated risk scores and data from national surveys (using data from adults aged 40-64 years) to estimate the proportion of the population at different levels of CVD risk for ten countries from different world regions as examples of the information the risk scores provide; we applied a risk threshold for high risk of at least 10% for high-income countries (HICs) and at least 20% for low-income and middle-income countries (LMICs) on the basis of national and international guidelines for CVD prevention. We estimated the proportion of men and women who were similarly categorised as high risk or low risk by the two risk scores.

findingsPredicted risks for the same risk factor profile were generally lower in HICs than in LMICs, with the highest risks in countries in central and southeast Asia and eastern Europe, including China and Russia. In HICs, the proportion of people aged 40-64 years at high risk of CVD ranged from 1% for South Korean women to 42% for Czech men (using a ≥10% risk threshold), and in low-income countries ranged from 2% in Uganda (men and women) to 13% in Iranian men (using a ≥20% risk threshold). More than 80% of adults were similarly classified as low or high risk by the laboratory-based and office-based risk scores. However, the office-based model substantially underestimated the risk among patients with diabetes.

interpretationOur risk charts provide risk assessment tools that are recalibrated for each country and make the estimation of CVD risk possible without using laboratory-based measurements.

fundingNational Institutes of Health.

Indexed as

AdultAgedCardiovascular DiseasesFemaleGlobal HealthHumansMaleMiddle AgedProspective StudiesRisk AssessmentRisk Factors

Identifiers

PMID28126460
PMCPMC5354360
OpenAlexW2582797328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.